• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

45% Increase in Aktana Next-Best-Engagement Suggestions Used in 2021 Demonstrates Surge in Artificial Intelligence (AI) Adoption


Aktana, a leader in intelligent customer engagement for the global life sciences industry, today reports new indicators of a shift in artificial intelligence (AI) implementation strategy in commercial life sciences. Notably, Aktana crossed a milestone of 30 million next-best-engagement (NBE) suggestions, including an unprecedented 45% increase in AI-driven omnichannel actions in 2021 directly impacting the customer experience of more than 700,000 healthcare professionals. Leading pharmaceutical companies are now scaling AI capabilities simultaneously across multiple geographies, therapeutic areas, and brands rather than taking a restrained, market-by-market approach.

Aktana’s modular solution enables commercial and medical teams from all-sized organizations to rapidly scale AI-driven programs to personalize the experience, coordinate engagement, and optimize the customer journey across channels.

LEO Pharma, for instance, is expanding use of Aktana’s Contextual Intelligence 360 platform across multiple European countries and Canada. “We want to leverage the power of AI to better support healthcare professionals with relevant information when they need it throughout the omnichannel journey,” said Marc Tàpies Llobet, senior director, commercial excellence in the EU at LEO. “The roll-out of Aktana’s solution globally is also key to increase the effectiveness of all our commercial teams with helpful next-best-action suggestions and insights.”

Related Videos
Related Content